Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis.

Billeskov R, Lindenstrøm T, Woodworth J, Vilaplana C, Cardona PJ, Cassidy JP, Mortensen R, Agger EM, Andersen P.

Front Immunol. 2018 Jan 15;8:1973. doi: 10.3389/fimmu.2017.01973. eCollection 2017.

2.

T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties.

Lindenstrøm T, Moguche A, Damborg M, Agger EM, Urdahl K, Andersen P.

EBioMedicine. 2018 Jan;27:27-39. doi: 10.1016/j.ebiom.2017.12.004. Epub 2017 Dec 7.

3.

The dynamics of immune responses to Mycobacterium tuberculosis during different stages of natural infection: A longitudinal study among Greenlanders.

Michelsen SW, Soborg B, Diaz LJ, Hoff ST, Agger EM, Koch A, Rosenkrands I, Wohlfahrt J, Melbye M.

PLoS One. 2017 Jun 1;12(6):e0177906. doi: 10.1371/journal.pone.0177906. eCollection 2017.

4.

Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Filskov J, Mikkelsen M, Hansen PR, Christensen JP, Thomsen AR, Andersen P, Bukh J, Agger EM.

J Virol. 2017 Jun 26;91(14). pii: e00130-17. doi: 10.1128/JVI.00130-17. Print 2017 Jul 15.

5.

Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6.

Ruhwald M, de Thurah L, Kuchaka D, Zaher MR, Salman AM, Abdel-Ghaffar AR, Shoukry FA, Michelsen SW, Soborg B, Blauenfeldt T, Mpagama S, Hoff ST, Agger EM, Rosenkrands I, Aagard C, Kibiki G, El-Sheikh N, Andersen P.

Sci Rep. 2017 Apr 7;7:45969. doi: 10.1038/srep45969.

6.

Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy.

Billeskov R, Wang Y, Solaymani-Mohammadi S, Frey B, Kulkarni S, Andersen P, Agger EM, Sui Y, Berzofsky JA.

J Immunol. 2017 May 1;198(9):3494-3506. doi: 10.4049/jimmunol.1600965. Epub 2017 Mar 27.

7.

The Memory Immune Response to Tuberculosis.

Kirman JR, Henao-Tamayo MI, Agger EM.

Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TBTB2-0009-2016. Review.

PMID:
28087940
8.

Host immunity to Mycobacterium tuberculosis and risk of tuberculosis: A longitudinal study among Greenlanders.

Michelsen SW, Soborg B, Agger EM, Diaz LJ, Hoff ST, Koch A, Sorensen HCF, Andersen P, Wohlfahrt J, Melbye M.

Vaccine. 2016 Nov 21;34(48):5975-5983. doi: 10.1016/j.vaccine.2016.09.047. Epub 2016 Oct 27.

PMID:
27997344
9.

Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants.

Olafsdottir TA, Lindqvist M, Nookaew I, Andersen P, Maertzdorf J, Persson J, Christensen D, Zhang Y, Anderson J, Khoomrung S, Sen P, Agger EM, Coler R, Carter D, Meinke A, Rappuoli R, Kaufmann SH, Reed SG, Harandi AM.

Sci Rep. 2016 Dec 13;6:39097. doi: 10.1038/srep39097.

10.

Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung.

Woodworth JS, Cohen SB, Moguche AO, Plumlee CR, Agger EM, Urdahl KB, Andersen P.

Mucosal Immunol. 2017 Mar;10(2):555-564. doi: 10.1038/mi.2016.70. Epub 2016 Aug 24.

11.

Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis.

Billeskov R, Tan EV, Cang M, Abalos RM, Burgos J, Pedersen BV, Christensen D, Agger EM, Andersen P.

PLoS One. 2016 Aug 15;11(8):e0161217. doi: 10.1371/journal.pone.0161217. eCollection 2016.

12.

The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons.

Carroll EC, Jin L, Mori A, Muñoz-Wolf N, Oleszycka E, Moran HBT, Mansouri S, McEntee CP, Lambe E, Agger EM, Andersen P, Cunningham C, Hertzog P, Fitzgerald KA, Bowie AG, Lavelle EC.

Immunity. 2016 Mar 15;44(3):597-608. doi: 10.1016/j.immuni.2016.02.004. Epub 2016 Mar 2.

13.

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.

Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, Fox CB, Meinke A, D'Oro U, Casini D, Bonci A, Billeskov R, De Gregorio E, Rappuoli R, Harandi AM, Andersen P, Agger EM.

Sci Rep. 2016 Jan 21;6:19570. doi: 10.1038/srep19570.

14.

Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Agger EM.

Adv Drug Deliv Rev. 2016 Jul 1;102:73-82. doi: 10.1016/j.addr.2015.11.012. Epub 2015 Nov 17. Review.

15.

Protein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infection.

Hoang T, Agger EM, Cassidy JP, Christensen JP, Andersen P.

Infect Immun. 2015 May;83(5):2118-26. doi: 10.1128/IAI.03030-14. Epub 2015 Mar 9.

16.

Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats.

Andreasen LV, Hansen LB, Andersen P, Agger EM, Dietrich J.

Vaccine. 2015 Apr 8;33(15):1873-9. doi: 10.1016/j.vaccine.2015.02.011. Epub 2015 Feb 17.

PMID:
25698487
17.

Human B cells produce chemokine CXCL10 in the presence of Mycobacterium tuberculosis specific T cells.

Hoff ST, Salman AM, Ruhwald M, Ravn P, Brock I, Elsheikh N, Andersen P, Agger EM.

Tuberculosis (Edinb). 2015 Jan;95(1):40-7. doi: 10.1016/j.tube.2014.10.005. Epub 2014 Oct 22.

PMID:
25476870
18.

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.

van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, O'Dee DM, Graves A, Thierry-Carstensen B, Andreasen LV, Ruhwald M, de Visser AW, Agger EM, Ottenhoff TH, Kromann I, Andersen P.

Vaccine. 2014 Dec 12;32(52):7098-107. doi: 10.1016/j.vaccine.2014.10.036. Epub 2014 Oct 30.

19.

An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines.

Jong WS, Daleke-Schermerhorn MH, Vikström D, Ten Hagen-Jongman CM, de Punder K, van der Wel NN, van de Sandt CE, Rimmelzwaan GF, Follmann F, Agger EM, Andersen P, de Gier JW, Luirink J.

Microb Cell Fact. 2014 Nov 25;13:162. doi: 10.1186/s12934-014-0162-8.

20.

Author's response: BCG and infection with Mycobacterium tuberculosis.

Michelsen SW, Agger EM, Hoff ST, Soborg B, Carstensen L, Koch A, Lillebaek T, Sorensen HC, Wohlfahrt J, Melbye M.

Thorax. 2015 Mar;70(3):286-7. doi: 10.1136/thoraxjnl-2014-206258. Epub 2014 Sep 17. No abstract available.

PMID:
25232042
21.

The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland.

Michelsen SW, Soborg B, Koch A, Carstensen L, Hoff ST, Agger EM, Lillebaek T, Sorensen HC, Wohlfahrt J, Melbye M.

Thorax. 2014 Sep;69(9):851-6. doi: 10.1136/thoraxjnl-2014-205688. Epub 2014 Jun 26.

PMID:
24969643
22.

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Dietrich J, Andreasen LV, Andersen P, Agger EM.

PLoS One. 2014 Jun 23;9(6):e100879. doi: 10.1371/journal.pone.0100879. eCollection 2014.

23.

High-frequency vaccine-induced CD8⁺ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection.

Lindenstrøm T, Aagaard C, Christensen D, Agger EM, Andersen P.

Eur J Immunol. 2014 Jun;44(6):1699-709. doi: 10.1002/eji.201344358. Epub 2014 Mar 27.

24.

Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation.

Woodworth JS, Aagaard CS, Hansen PR, Cassidy JP, Agger EM, Andersen P.

J Immunol. 2014 Apr 1;192(7):3247-58. doi: 10.4049/jimmunol.1300283. Epub 2014 Feb 26.

25.

Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics.

Knudsen NP, Nørskov-Lauritsen S, Dolganov GM, Schoolnik GK, Lindenstrøm T, Andersen P, Agger EM, Aagaard C.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1096-101. doi: 10.1073/pnas.1314973111. Epub 2014 Jan 6.

26.

ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.

Hoang T, Aagaard C, Dietrich J, Cassidy JP, Dolganov G, Schoolnik GK, Lundberg CV, Agger EM, Andersen P.

PLoS One. 2013 Dec 12;8(12):e80579. doi: 10.1371/journal.pone.0080579. eCollection 2013.

27.

Interview: an insight into cutting-edge tuberculosis vaccine research. Interview by Katie Lockwood.

Agger EM.

Immunotherapy. 2013 Aug;5(8):799-801. doi: 10.2217/imt.13.80.

28.

The physical stability of the recombinant tuberculosis fusion antigens h1 and h56.

Hamborg M, Kramer R, Schanté CE, Agger EM, Christensen D, Jorgensen L, Foged C, Middaugh CR.

J Pharm Sci. 2013 Oct;102(10):3567-78. doi: 10.1002/jps.23669. Epub 2013 Jul 19.

PMID:
23873630
29.

Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant.

Korsholm KS, Karlsson I, Tang ST, Brandt L, Agger EM, Aagaard C, Andersen P, Fomsgaard A.

PLoS One. 2013 May 17;8(5):e63575. doi: 10.1371/journal.pone.0063575. Print 2013.

30.

Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells.

Lindenstrøm T, Knudsen NP, Agger EM, Andersen P.

J Immunol. 2013 Jun 15;190(12):6311-9. doi: 10.4049/jimmunol.1300248. Epub 2013 May 15.

31.
32.

The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling.

Desel C, Werninghaus K, Ritter M, Jozefowski K, Wenzel J, Russkamp N, Schleicher U, Christensen D, Wirtz S, Kirschning C, Agger EM, Prazeres da Costa C, Lang R.

PLoS One. 2013;8(1):e53531. doi: 10.1371/journal.pone.0053531. Epub 2013 Jan 7.

33.

Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset.

Lindenstrøm T, Woodworth J, Dietrich J, Aagaard C, Andersen P, Agger EM.

Infect Immun. 2012 Oct;80(10):3533-44. doi: 10.1128/IAI.00550-12. Epub 2012 Jul 30.

34.

A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.

Christensen D, Henriksen-Lacey M, Kamath AT, Lindenstrøm T, Korsholm KS, Christensen JP, Rochat AF, Lambert PH, Andersen P, Siegrist CA, Perrie Y, Agger EM.

J Control Release. 2012 Jun 28;160(3):468-76. doi: 10.1016/j.jconrel.2012.03.016. Epub 2012 Mar 27.

PMID:
22709414
35.

Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses.

Kamath AT, Mastelic B, Christensen D, Rochat AF, Agger EM, Pinschewer DD, Andersen P, Lambert PH, Siegrist CA.

J Immunol. 2012 May 15;188(10):4828-37. doi: 10.4049/jimmunol.1103183. Epub 2012 Apr 13.

36.

The effect of adjuvants on the immune response induced by a DBL4ɛ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria.

Pinto VV, Salanti A, Joergensen LM, Dahlbäck M, Resende M, Ditlev SB, Agger EM, Arnot DE, Theander TG, Nielsen MA.

Vaccine. 2012 Jan 11;30(3):572-9. doi: 10.1016/j.vaccine.2011.11.068. Epub 2011 Nov 26.

PMID:
22122859
37.

CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.

Hansen J, Lindenstrøm T, Lindberg-Levin J, Aagaard C, Andersen P, Agger EM.

Cancer Immunol Immunother. 2012 Jun;61(6):893-903. doi: 10.1007/s00262-011-1156-6. Epub 2011 Nov 18.

PMID:
22095092
38.

License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems.

Foged C, Hansen J, Agger EM.

Eur J Pharm Sci. 2012 Mar 12;45(4):482-91. doi: 10.1016/j.ejps.2011.08.016. Epub 2011 Aug 25. Review.

PMID:
21888971
39.

CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets.

Martel CJ, Agger EM, Poulsen JJ, Hammer Jensen T, Andresen L, Christensen D, Nielsen LP, Blixenkrone-Møller M, Andersen P, Aasted B.

PLoS One. 2011;6(8):e22891. doi: 10.1371/journal.pone.0022891. Epub 2011 Aug 5.

40.

Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes.

Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ, Lindenstrøm T, Enouf V, van der Werf S, Andersen P, Agger EM.

Vaccine. 2011 Aug 26;29(37):6283-91. doi: 10.1016/j.vaccine.2011.06.040. Epub 2011 Jun 29.

PMID:
21722683
41.

Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant.

Hitzler I, Oertli M, Becher B, Agger EM, Müller A.

Gastroenterology. 2011 Jul;141(1):186-96, 196.e1. doi: 10.1053/j.gastro.2011.04.009. Epub 2011 Apr 16.

PMID:
21569773
42.

The C-terminally encoded, MHC class II-restricted T cell antigenicity of the Helicobacter pylori virulence factor CagA promotes gastric preneoplasia.

Arnold IC, Hitzler I, Engler D, Oertli M, Agger EM, Müller A.

J Immunol. 2011 Jun 1;186(11):6165-72. doi: 10.4049/jimmunol.1003472. Epub 2011 Apr 25.

43.

Cationic liposomes as vaccine adjuvants.

Christensen D, Korsholm KS, Andersen P, Agger EM.

Expert Rev Vaccines. 2011 Apr;10(4):513-21. doi: 10.1586/erv.11.17. Review.

PMID:
21506648
44.

Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.

McNeil SE, Rosenkrands I, Agger EM, Andersen P, Perrie Y.

J Pharm Sci. 2011 May;100(5):1856-65. doi: 10.1002/jps.22427. Epub 2010 Dec 10.

PMID:
21374619
45.

Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis.

Christensen D, Lindenstrøm T, van de Wijdeven G, Andersen P, Agger EM.

PLoS One. 2010 Nov 29;5(11):e15043. doi: 10.1371/journal.pone.0015043.

46.
47.

Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.

Nordly P, Rose F, Christensen D, Nielsen HM, Andersen P, Agger EM, Foged C.

J Control Release. 2011 Mar 30;150(3):307-17. doi: 10.1016/j.jconrel.2010.11.021. Epub 2010 Nov 25.

PMID:
21111765
48.

Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.

Nordly P, Agger EM, Andersen P, Nielsen HM, Foged C.

Pharm Res. 2011 Mar;28(3):553-62. doi: 10.1007/s11095-010-0301-9. Epub 2010 Nov 2.

PMID:
21042837
49.

Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo.

Nordly P, Korsholm KS, Pedersen EA, Khilji TS, Franzyk H, Jorgensen L, Nielsen HM, Agger EM, Foged C.

Eur J Pharm Biopharm. 2011 Jan;77(1):89-98. doi: 10.1016/j.ejpb.2010.10.001. Epub 2010 Oct 20.

PMID:
20940050
50.

Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response.

Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, Perrie Y.

J Control Release. 2010 Jul 14;145(2):102-8. doi: 10.1016/j.jconrel.2010.03.027. Epub 2010 Apr 8.

PMID:
20381556

Supplemental Content

Loading ...
Support Center